Abstract：
BACKGROUND: Hyperkalemia is common among end-stage renal disease (ESRD) patients, and consequently contributes to an increased risk of cardiac arrhythmia. Senna glycoside may decrease colonic transit time and potassium colonic reabsorption.
METHODS: Patients on hemodialysis were randomized to receive either oral senna glycoside (n = 37) or control (n = 36) for 8 weeks. The primary outcomes were predialysis serum potassium and prevalence of hyperkalemia.
RESULTS: At the end of the study, significantly reduced serum potassium concentrations were observed in the senna glycoside compared with the control (-0.32 [95%CI -0.43, -0.04] vs. -0.02 [95%CI -0.12, 0.05] mEq/L, p < 0.001, respectively). The prevalence of hyperkalemia during the study occurred at 13.8% in the control and 5.4% in the senna glycoside (p = 0.309). No serious adverse events were observed.
CONCLUSIONS: Among patients with ESRD on hemodialysis, senna glycoside significantly decreases serum potassium level. Senna glycoside is a safe and possibly effective alternative treatment for hyperkalemia in ESRD.
METHODS: Patients on hemodialysis were randomized to receive either oral senna glycoside (n = 37) or control (n = 36) for 8 weeks. The primary outcomes were predialysis serum potassium and prevalence of hyperkalemia.
RESULTS: At the end of the study, significantly reduced serum potassium concentrations were observed in the senna glycoside compared with the control (-0.32 [95%CI -0.43, -0.04] vs. -0.02 [95%CI -0.12, 0.05] mEq/L, p < 0.001, respectively). The prevalence of hyperkalemia during the study occurred at 13.8% in the control and 5.4% in the senna glycoside (p = 0.309). No serious adverse events were observed.
CONCLUSIONS: Among patients with ESRD on hemodialysis, senna glycoside significantly decreases serum potassium level. Senna glycoside is a safe and possibly effective alternative treatment for hyperkalemia in ESRD.
摘要：
背景：高钾血症在终末期肾病（ESRD）患者中很常见，并因此导致心律失常的风险增加。番泻叶苷可以减少结肠运输时间和钾结肠重吸收。
方法：接受血液透析的患者随机接受8周的口服番泻叶苷（n=37）或对照组（n=36）。主要结果是透析前血清钾和高钾血症的患病率。
结果：在研究结束时，与对照组相比，番泻叶苷中的血清钾浓度显着降低（-0.32[95CI-0.43，-0.04]vs.-0.02[95CI-0.12，0.05]mEq/L，p分别<0.001)。研究期间高钾血症的患病率在对照组中为13.8％，在番泻叶苷中为5.4％（p=0.309）。未观察到严重不良事件。
结论：在进行血液透析的ESRD患者中，番泻叶苷显著降低血清钾水平。番泻叶苷是ESRD高钾血症的安全且可能有效的替代疗法。
方法：接受血液透析的患者随机接受8周的口服番泻叶苷（n=37）或对照组（n=36）。主要结果是透析前血清钾和高钾血症的患病率。
结果：在研究结束时，与对照组相比，番泻叶苷中的血清钾浓度显着降低（-0.32[95CI-0.43，-0.04]vs.-0.02[95CI-0.12，0.05]mEq/L，p分别<0.001)。研究期间高钾血症的患病率在对照组中为13.8％，在番泻叶苷中为5.4％（p=0.309）。未观察到严重不良事件。
结论：在进行血液透析的ESRD患者中，番泻叶苷显著降低血清钾水平。番泻叶苷是ESRD高钾血症的安全且可能有效的替代疗法。
